Healthcare: 3 Beaten-Up Biotechs -- Are They Buys?

Industry Focus - Podcast tekijän mukaan The Motley Fool

kokeile Podimo ilmaiseksi 30! päivän ajan

kokeile Podimo ilmaiseksi 30! päivän ajan

universumia joka on täynnä satoja podcasteja ja äänikirjoja, klikkaa tätä kokeillaksesi

 Sponsored

Kategoriat:

Talous

Here's why post-approval setbacks have caused Puma Biotechnology, Clovis Oncology, and Regenxbio shares to tumble, and if any of these stocks are finally worth buying. Stocks: PBYI, CLVS, RGNX Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter

Visit the podcast's native language site